Included physical activity questions in 2000, assessing health outcomes through annual health questionnaire through 2014 (mean ± SD follow-up = 10.7 ± 3.7 yr). Incident type 2 diabetes (N cases = 2120) and cardiovascular disease (N cases = 1742) were confirmed on medical record review. Cases of cardiovascular disease were defined as confirmed cases of myocardial infarction, stroke, coronary artery bypass graft, angioplasty, or cardiovascular disease death. Results Compared with women who reported no strength training, women engaging in any strength training experienced a reduced rate of type 2 diabetes of 30% (hazard ratio = 0.70, 95% confidence interval = 0.61–0.80) when controlling for time spent in other activities and other confounders. A risk reduction of 17% was observed for cardiovascular disease among women engaging in strength training (hazard ratio = 0.83, 95% confidence interval = 0.72, 0.96). Participation in both strength training and aerobic activity was associated with additional risk reductions for both type 2 diabetes and cardiovascular disease compared with participation in aerobic activity only. Conclusions These data support the inclusion of muscle-strengthening exercises in physical activity regimens for reduced risk of type 2 diabetes and cardiovascular disease, independent of aerobic exercise. Further research is needed to determine the optimum dose and intensity of muscle-strengthening exercises....

Purpose: This study aimed to examine how accelerometer-assessed physical activity accumulation patterns (e.g., is activity performed daily or only 1 or 2 d·wk⁻¹ or is activity accrued in bouts) may affect the association with mortality. Methods: Adults (N = 3438), age 40 yr and older, who wore an accelerometer (ActiGraph 7164), were drawn from the longitudinal follow-up of the National Health and Nutritional Examination Survey (2003–2006), a population-based survey of the United States. Accelerometer-assessed moderate-to-vigorous physical activity (MVPA) was described by activity patterns. Participants engaging in the majority of their activity on only 1 or 2 d·wk⁻¹· were classified as “weekend warriors.” Activity bouts were defined as a period of at least moderate intensity lasting at least 10 min. Bout characteristics included bout frequency and length. Mortality was assessed through National Death Index matching through 2013. Mortality rates were compared among groups with different activity patterns. Results: Over an average follow-up of 77.4 months, 394 deaths occurred. Compared to participants with <37.5 min of MVPA per week, those with greater amounts of activity had a 60% to 69% mortality rate reduction after adjusting for relevant covariables. Similar risk reductions were found when contrasting weekend warriors with those who were more frequently active. An increase of one MVPA bout per week was associated with a 13% increased mortality rate. Bout duration was not associated with mortality. Conclusion: Physical activity is associated with decreased mortality rate, even among those who are active 1 or 2 d·wk⁻¹.

Accelerometers’ accuracy for sedentary time (ST) and moderate-to-vigorous physical activity (MVPA) classification depends on accelerometer placement, data processing, activities, and sample characteristics. As intensities differ by age, this study sought to determine intensity cut-points at various wear locations people more than 70 years old. Data from 59 older adults were used for calibration and from 21 independent participants for cross-validation purposes. Participants wore accelerometers on their hip and wrists while performing activities and having their energy expenditure measured with portable calorimetry. ST and MVPA were defined as ≤1.5 metabolic equivalents (METs) and ≥3 METs (1 MET = 2.8 mL/kg/min), respectively. Receiver operator characteristic (ROC) analyses showed fair-to-good accuracy (area under the curve [AUC] = 0.62–0.89). ST cut-points were 7 mg (cross-validation: sensitivity = 0.88, specificity = 0.80) and 1 count/5 s (cross-validation: sensitivity = 0.91, specificity = 0.96) for the hip; 18 mg (cross-validation: sensitivity = 0.86, specificity = 0.86) and 102 counts/5 s (cross-validation: sensitivity = 0.91, specificity = 0.92) for the non-dominant wrist; and 22 mg and 175 counts/5 s (not cross-validated) for the dominant wrist. MVPA cut-points were 14 mg (cross-validation: sensitivity = 0.70, specificity = 0.99) and 54 count/5 s (cross-validation: sensitivity = 1.00, specificity = 0.96) for the hip; 60 mg (cross-validation: sensitivity = 0.83, specificity = 0.99) and 182 counts/5 s (cross-validation: sensitivity = 1.00, specificity = 0.89) for the non-dominant wrist; and 64 mg and 268 counts/5 s (not cross-validated) for the dominant wrist. These cut-points can classify ST and MVPA in older adults from hip- and wrist-worn accelerometers.